Table 1 Comparison of the demographic, clinical and laboratory measurements in the study groups
From: Relationship between galectin-3 level and disease activity in ankylosing spondylitis patients
Variables | Patient group (n = 45) | Control group (n = 35) | P values |
|---|---|---|---|
Age (years), mean ± SD | 40.75 ± 11.67 | 38.68 ± 8.56 | 0.38 |
Gender (female/male), n (%) | 17/28 (37.77/62.22) | 15/20 (33.33/44.44) | 0.64 |
BMI (kg/m2), mean ± SD | 27.34 ± 2.57 | 26.79 ± 3.03 | 0.38 |
Disease duration (years), mean ± SD | 7.44 ± 4.00 | ||
History of peripheral arthritis, n (%) | 9 (20) | ||
History of uveitis, n (%) | 6 (13.33) | ||
HLA-B27 positivity, n (%) | 37 (82.22) | ||
Galectin-3 (ng/mL), mean ± SD | 15.79 ± 5.17 | 13.72 ± 3.54 | 0.04 |
CRP ( mg/dL), mean ± SD | 1.55 ± 0.97 | 0.64 ± 0.34 | < 0.001 |
ESR (mm/h), mean ± SD | 21.80 ± 9.49 | 12.97 ± 2.53 | < 0.001 |
BASDAI ± SD | 2.63 ± 0.99 | ||
ASDAS-CRP ± SD | 1.60 ± 0.56 | ||
NSAID, n (%) | 9 (20) | ||
INF, n (%) | 11 (24.44) | ||
ETN, n (%) | 6 (13.33) | ||
ADA, n (%) | 14 (31.11) | ||
GOL, n (%) | 5 (11.11) |